First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
Basic Information
ID: ALA4732105
Journal: Eur J Med Chem
Title: First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
Authors: Wei M,Zhao R,Cao Y,Wei Y,Li M,Dong Z,Liu Y,Ruan H,Li Y,Cao S,Tang Z,Zhou Y,Song W,Wang Y,Wang J,Yang G,Yang C
Abstract: A growing number of reports suggested that the inhibitor targeting cyclin-dependent kinases (CDK) 2/4/6 can act as a more feasible chemotherapy strategy. In the present paper, a novel PROTAC molecule was developed based on the structure of Ribociclib's derivative. In malignant melanoma cells, the degrader can not only degrade CDK 2/4/6 simultaneously and effectively, but also remarkably induce cell cycle arrest and apoptosis of melanoma cells. Moreover, PROTAC molecules with CRBN ligands always have poor oral bioavailability. We developed the orally bioavailable prodrug for the first time. It would provide general solution for oral administration of the PROTAC molecules, derived from CRBN ligands, for animal test conveniently.
CiteXplore: 33256948
DOI: 10.1016/j.ejmech.2020.112903
Patent ID: ┄